Physician profile
Icem E Brewer
NPI 1316166697
$2,055.36
in general payments reported to CMS, 2019-2025
9 companies · $92.32 in 2025
The $92.32 reported for 2025 was less than what a typical Corneal and Contact Management provider received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $211 · 2021: $445 · 2022: $315 · 2023: $462 · 2024: $337 · 2025: $92.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $828 · Entertainment: $63.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.66 |
| Entertainment | $63.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,618.21 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $125.16 | 2022-2024 | Infuse, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $108.78 | 2019-2021 | |
| Optos, INC. | $63.09 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Alcon Vision LLC | $53.43 | 2019-2021 | |
| Biotissue Holdings INC. | $38.74 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $18.78 | 2024 | Xdemvy |
| Abbvie INC. | $16.53 | 2022 | |
| Coopervision INC. | $12.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Icem Brewer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.